Viloxazine Dosage

Medically reviewed by Drugs.com. Last updated on Jun 18, 2024.

Applies to the following strengths: 100 mg; 150 mg; 200 mg

Usual Pediatric Dose for:

Attention Deficit Disorder

Additional dosage information:

Renal Dose Adjustments
Liver Dose Adjustments
Precautions
Dialysis
Other Comments

Usual Pediatric Dose for Attention Deficit Disorder

6 to 11 years:
Initial dose: 100 mg orally once a day

May titrate in increments of 100 mg per week based on response and tolerability

Maximum dose: 400 mg/day

12 to 17 years:
Initial dose: 200 mg orally once a day

After 1 week, may titrate to 400 mg once a day based on response and tolerability

Maximum dose: 400 mg/day

Comments:

Assess heart rate and blood pressure prior to initiating treatment.
Screen patients for a personal or family history of suicide, bipolar disorder, and depression prior to initiating treatment.
Pharmacologic treatment for Attention-Deficit Hyperactivity Disorder (ADHD) may be needed for extended periods; periodically reevaluate and adjust dosage as needed.

Use: For the treatment of ADHD in pediatric patients 6 years or older.

Renal Dose Adjustments

Mild to moderate (estimated glomerular filtration rate [eGFR] 30 to 89 mL/min/1.73 m2): No adjustment recommended

Severe renal impairment (eGFR less than 30 mL/min/1.73 m2):

Initial dose: 100 mg orally once a day
May titrate in increments of 50 to 100 mg weekly based on response and tolerability
Maximum dose: 200 mg/day

Liver Dose Adjustments

Not recommended

Precautions

US BOXED WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behavior were reported in pediatric patients with ADHD receiving this drug than in patients treated with placebo.
Closely monitor patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS:

Concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis
Concomitant use of sensitive CYP450 1A2 substrates or CYP450 1A2 substrates with a narrow therapeutic range

Safety and efficacy have not been established in patients younger than 6 years or older than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

Take orally once a day with or without food; do not cut, crush, or chew the capsules
May open capsule and sprinkle contents over a teaspoon of applesauce; consume in its entirety within 2 hours without chewing

Storage requirements:

If mixed with applesauce, use within 2 hours; do not store for future use

Monitoring:

Assess heart rate and blood pressure prior to therapy, following any dose increase, and periodically during therapy
Screen for personal or family history of suicide, bipolar disorder, and depression prior to therapy
Monitor weight
Monitor for clinical worsening and emergence of suicidal thoughts and behaviors, especially during therapy initiation and with dose changes

Patient advice:

Patients/caregivers should be instructed to read the US FDA-approved patient labeling (Medication Guide).
Family members and caregivers should be informed of the possibility of suicidal thoughts and behaviors and instructed to report behavioral changes or emergence of suicidal thoughts and behaviors promptly.
Patients/caregivers should understand that there is a potential for somnolence and fatigue; they should understand how this drug affects them prior to engaging in activities requiring mental alertness.